Indivior PLC
IZQVF
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.05B
Close$
Share Statistics
| Market cap | $5.05 Billion |
|---|---|
| Enterprise Value | $4.94 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $- |
| Beta | -0.06 |
| Outstanding Shares | - |
Return
| Return on Equity | -175.00% |
|---|---|
| Return on Assets | 21.05% |
| Return on Invested Capital | 81.10% |
Valuation & Multiples
| P/E Ratio | 20.15 |
|---|---|
| PEG | 22.55 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.83 |
| Enterprise Value to EBIT | 14.58 |
| Enterprise Value to Net Income | 19 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | -0.44 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Indivior Plc
CEO: Shaun Thaxter Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, Subutex Tablet, ...